MetastaticCRC: After the CORRECT trial, two phase 3 trials (CONSIGN, CONCUR) showed benefits compared to placebo.<unk>  dosing was 150 or 160 mg/d for first 3 weeks of each 4 week cycle.
Regorafenib
Sorafenib
Encorafenib
Tucatinib
Brigatinib
Fostamatinib
Capmatinib
Lapatinib